Back to Research News Research News and Information
Research Presented at American Diabetes Association 57th Annual Meeting and Scientific Sessions Supports Development of Alternative Glucose Testing Technique

ST. PAUL, Minn., June 23 /PRNewswire/ -- At the Annual Meeting and Scientific Sessions of the American Diabetes Association in Boston, June 21-24, investigators presented the results of two clinical studies that confirmed the use of interstitial fluid (ISF) the clear fluid between cells found throughout the body and skin as an alternative, bloodless method for measuring glucose. The studies conducted at the Mayo Clinic, Rochester, Minn., and the University of Minnesota, Minn., found that glucose levels in ISF correlate with glucose levels in blood samples taken from fingertips and veins.

These findings support the development of a less-invasive glucose measurement technology, using ISF from skin, for people with diabetes, thereby eliminating the pain of lancing their fingertips to obtain a blood sample. In the United States, 16 million people have diabetes and 625,000 new cases are diagnosed each year.

According to John Service, M.D., the Mayo Clinic study compared the glucose concentrations of minute quantities of skin ISF with glucose concentrations of blood taken from fingertips and veins in 67 participants. The study concluded that ISF sampling from the skin is a bloodless, less-invasive technique with ISF glucose results matching blood glucose results.

The University of Minnesota study compared skin ISF with blood samples taken from fingertips and veins over a five-hour period before and after breakfast when glucose levels were changing rapidly. John Bantle, M.D., reported a high correlation between ISF glucose levels and blood glucose levels under changing glucose conditions. Dr. Bantle said, "We concluded that dermal interstitial fluid (ISF) glucose level can reliably estimate plasma glucose."

Both studies were funded by St. Paul, Minn.-based Integ Incorporated (Nasdaq: NTEG), and confirm early scientific research indicating that glucose levels in ISF correlate closely with blood glucose levels. Integ is developing the LifeGuide(TM) System, a next-generation hand-held glucose meter that will allow people with diabetes to self-monitor their glucose levels frequently, without experiencing the pain and mess of lancing their fingers to obtain a blood sample. Integ plans to introduce the LifeGuide System after receiving U.S. Food and Drug Administration premarket notification clearance.

Diabetes is a chronic disease, characterized by the body's inability to maintain the proper amount of circulating glucose. Glucose is derived from carbohydrates in food and is circulated through the body where it is converted into energy. Insulin -- a hormone secreted by the pancreas -- is the body's primary regulatory mechanism for maintaining proper glucose levels.

Diabetes is caused by a reduction in insulin or a resistance to insulin. People with diabetes are subject to significant complications affecting their overall health and life expectancy, unless the disease is managed correctly. In the United States, diabetes is a leading cause of blindness, kidney disease, heart failure and amputation, and is the fourth leading cause of death by disease.

Glucose monitoring is an essential element of diabetes management. Traditional blood glucose monitoring systems employ a "finger stick" method of obtaining a blood sample. The ISF monitoring technique is less invasive and uses an ISF sample obtained by holding a sample collection device against the skin. Integ Incorporated, based in St. Paul, Minn., was founded in 1990 to develop, manufacture and market the LifeGuide(TM) System.

SOURCE Integ Incorporated -0- 6/23/97 /CONTACT: David Talen, Marketing Manager of Integ Incorporated, 612-639-8816, web site, or Nancy A. Johnson of Padilla Speer Beardsley Inc. for Integ, 612-871-8877, e-mail: (NTEG)

Reprinted from a report in PRNewswire.

  Back to Research News Return to the Top of This Page

Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.